Drug
Eculizumab clinical trials
Also written Soliris.
- studies test it
- 80
- open now
- 5
- in phase 3
- 28
- first study started
- 2004
Keep track of what changes. Save the eculizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Biosimilars in development
- ABP 959
- 2
- BCD-148
- 2
- SB12
- 1
Studies by the year they started
79 studies that test it; most in 2009 (8); 1 more planned to start later
| Year | Studies |
|---|---|
| 2004 | 4 |
| 2005 | 2 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 8 |
| 2010 | 5 |
| 2011 | 6 |
| 2012 | 5 |
| 2013 | 3 |
| 2014 | 6 |
| 2015 | 5 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 6 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 5 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 4 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 12
- Phase 2
- 45
- Phase 3
- 28
- Phase 4
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 41 · Other 39
Alexion Pharmaceuticals, Inc. (32) · National Heart, Lung, and Blood Institute (NHLBI) (3) · Mayo Clinic (3) · Assistance Publique - Hôpitaux de Paris (3) · Tianjin Medical University General Hospital (2) · Biocad (2) · Samsung Bioepis Co., Ltd. (2) · Johns Hopkins University (2)
Often tested with
Tested in the same studies.
Ravulizumab (2) · HRS-5965 (1) · Danicopan (1) · Ruxoprubart (1) · Satralizumab (1) · Inebilizumab (1)
Studies
Open first, then newest update. How each study uses eculizumab is read from its arms, and is right about nine times in ten.
Testing it · 80
- Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSDRecruitingPhase 4Massachusetts General HospitalNCT07010302Written as Eculizumab (Soliris®)
- Safety and Efficacy of Eculizumab in High-risk TA-TMARecruitingPhase 2First Affiliated Hospital of Zhejiang UniversityNCT07707687Written as Eculizumab
- Study of NM8074 in Adult PNH Patients With Inadequate Response to SolirisNot yet recruitingPhase 2NovelMed TherapeuticsNCT05646563Written as Soliris
- Eculizumab for Prevention of Antibody-Mediated Rejection in ABO-Incompatible Living Donor Kidney TransplantationNot yet recruitingPhase 1/2Tao LinNCT06453135Written as Eculizumab
- Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic SyndromeRecruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT05726916Written as Soliris®
- Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUSCompletedPhase 4Nantes University HospitalNCT02574403Written as eculizumab
- Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum DisorderActive, not recruitingPhase 2Tianjin Medical University General HospitalNCT07184840Written as Complement protein C5 inhibitor
- Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in ChinaCompletedPhase 3Alexion Pharmaceuticals, Inc.NCT05886244Written as Eculizumab
- Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHUCompletedPhase 3University Hospital, ToulouseNCT02205541Written as Eculizumab
- Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMGCompletedPhase 3Alexion Pharmaceuticals, Inc.NCT06764160Written as Eculizumab
- Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSDActive, not recruitingPhase 3Alexion Pharmaceuticals, Inc.NCT06724809Written as eculizumab
- Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in ChinaCompletedPhase 3Alexion Pharmaceuticals, Inc.NCT05876351Written as Eculizumab
- Complement C5 mAb in the Treatment of Anti-GBM DiseaseCompletedPhase 2Peking University First HospitalNCT06513338Written as Eculizumab
- Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney TransplantationWithdrawnPhase 1/2Assistance Publique - Hôpitaux de ParisNCT02113891Written as Eculizumab
- A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor TherapyCompletedPhase 3Chengdu Suncadia Medicine Co., Ltd.NCT06593938Written as Eculizumab Injection
- Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum DisorderWithdrawnPhase 2Tianjin Medical University General HospitalNCT06673394Written as Complement protein C5 inhibitor
- A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré SyndromeCompletedPhase 3Alexion Pharmaceuticals, Inc.NCT04752566Written as Eculizumab
- An Extension Clinical Study of BCD-148 for the Treatment of Patients With PNH Previously Treated in Clinical Study No. BCD-148-2/NOCTURNCompletedPhase 3BiocadNCT06987864Written as eculizumab
- A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)CompletedPhase 3Alexion Pharmaceuticals, Inc.NCT03759366Written as Eculizumab
- A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum DisorderTerminatedPhase 2/3Alexion Pharmaceuticals, Inc.NCT04155424Written as Eculizumab
See all 80 studies that test eculizumab →
Given in every arm · 5 — eculizumab is usual care beside what is tested
- A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor TreatmentActive, not recruitingPhase 3Regeneron PharmaceuticalsNCT05133531Written as Eculizumab
- A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)TerminatedPhase 2BioCryst PharmaceuticalsNCT04702568Written as Eculizumab
- Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal HemoglobinuriaTerminatedPhase 3Regeneron PharmaceuticalsNCT05131204Written as Eculizumab
- Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedPhase 3Apellis Pharmaceuticals, Inc.NCT03500549Written as Soliris
- Clinical Trial of BCD-148 and Soliris® for the Treatment of Patients With Paroxysmal Nocturnal HemoglobinuriaCompletedPhase 3BiocadNCT04060264Written as BCD-148
As the comparator · 14 — what is tested is compared with eculizumab
- A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor TherapyNot yet recruitingPhase 3Bisirna Therapeutics (Suzhou) Co., Ltd.NCT07816237Written as Eculizumab (Soliris®)
- A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH.Not yet recruitingPhase 3Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.NCT07747090Written as Eculizumab infusion
- A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria PatientsNot yet recruitingPhase 3Nanjing Chia-tai Tianqing PharmaceuticalNCT07177859Written as Eculizumab Injection
- Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor TherapyRecruitingPhase 3Wuhan Createrna Science and Technology Co., LtdNCT06932744Written as Eculizumab Injection
- Comparative PK, Safety, Tolerability, Immunogenicity, and PD Profile Study of TUR03 and Soliris in Healthy ParticipantsRecruitingPhase 1Turgut Ardika PTY LTDNCT05863442Written as Soliris 300 MG in 30 ML Injection
- A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement InhibitorsActive, not recruitingPhase 3Hoffmann-La RocheNCT04434092Written as Eculizumab
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement InhibitorsActive, not recruitingPhase 3Hoffmann-La RocheNCT04432584Written as Eculizumab
- Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney TxCompletedPhase 3Hansa Biopharma ABNCT04935177Written as Eculizumab
- A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor TherapyCompletedPhase 3Haisco Pharmaceutical Group Co., Ltd.NCT06799546Written as Eculizumab Injection
- ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With EculizumabCompletedPhase 3Alexion Pharmaceuticals, Inc.NCT03056040Written as Eculizumab
- BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor TherapyTerminatedPhase 2BioCryst PharmaceuticalsNCT05116774Written as Eculizumab
- Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody TreatmentCompletedPhase 3Novartis PharmaceuticalsNCT04558918Written as Eculizumab
- ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedPhase 3Alexion Pharmaceuticals, Inc.NCT02946463Written as Eculizumab
- Clinical Trial of BCD-148 and Soliris® for the Treatment of Patients With Paroxysmal Nocturnal HemoglobinuriaCompletedPhase 3BiocadNCT04060264Written as BCD-148
Codes
What other systems call eculizumab · ClinicalTrials.gg INT004609
- MeSH (NLM) C481642eculizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) A3ULP0F556ECULIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 591781Confirmed FDA, Wikidata
- Wikidata Q421617eculizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C48386EculizumabOne source FDA
- DrugBank DB01257One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C481642 | eculizumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | A3ULP0F556 | ECULIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 591781 | — | Confirmed FDA, Wikidata |
| Wikidata | Q421617 | eculizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C48386 | Eculizumab | One source FDA |
| DrugBank | DB01257 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.